Xencor to present Phase 1 XmAb819 data in advanced kidney cancer at ESMO 2026 - XNCR News | RalliesXencor to present Phase 1 XmAb819 data in advanced kidney cancer at ESMO 2026
X
XNCR• Phase 1 XmAb819 data set for ESMO 2026 presentation
- Xencor flagged Phase 1 results for XmAb819 in advanced clear cell renal cell carcinoma for a proffered oral presentation at ESMO 2026.
- Abstract scheduled for release on Oct. 18 at 3:05 p.m. PDT; presentation slated for the Oct. 23-27 congress in Madrid.
- Program positioned to support dose selection for a planned Phase 3 pivotal study in advanced clear cell renal cell carcinoma.
•
